This trial supports the benefit of using platinum-based regimen as an upfront systemic therapy for patients with germline BRCA1/BRCA2-associated advanced pancreatic cancer as the OS in both arms was superior compared with historical data (median OS 15.5 months with gemcitabine/cisplatin and 16.4 months with gemcitabine/cisplatin/veliparib). Here, BRCA2 is linked to familial pancreatic carcinoma.